Tiziana Life Sciences director reports holdings

Tiziana Life Sciences Ltd director and more-than-10% owner Gabriele M. Cerrone filed an initial ownership report showing substantial holdings in the company’s common stock and options.

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd director and more-than-10% owner Gabriele M. Cerrone filed an initial ownership report showing substantial holdings in the company’s common stock and options. The filing lists direct ownership of 44,654,830 shares of common stock.

It also shows options over 1,629,702 shares of common stock at an exercise price of $0.88 per share expiring on May 6, 2028, plus four option positions over 250,000 underlying shares each at an exercise price of $0.71 per share expiring on May 3, 2034. According to a footnote, these options are exercisable upon the achievement of certain performance conditions.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider CERRONE GABRIELE M

Role Director, 10% Owner

Type	Security	Shares	Price	Value
holding	Options	--	--	--
holding	Options	--	--	--
holding	Options	--	--	--
holding	Options	--	--	--
holding	Options	--	--	--
holding	COMMON STOCK	--	--	--

Holdings After Transaction: Options — 2,629,702 contracts (Direct); COMMON STOCK — 44,654,830 shares (Direct)

Footnotes (1)

1. F1. Exercisable upon the achievement of certain performance conditions

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Gabriele M. Cerrone’s Form 3 for Tiziana Life Sciences (TLSA) show?

The Form 3 shows Gabriele M. Cerrone as a director and more-than-10% owner of Tiziana Life Sciences, with large direct holdings of common stock and multiple option positions over additional common shares at specified exercise prices and expiration dates.

How many Tiziana Life Sciences (TLSA) common shares does Gabriele M. Cerrone report owning?

He reports directly owning 44,654,830 shares of Tiziana Life Sciences common stock. This figure comes from the common stock line where total shares following the reported holdings are shown, indicating a significant equity position in the company.

What stock options over TLSA shares are reported at the $0.88 exercise price?

The filing lists options over 1,629,702 underlying shares of Tiziana Life Sciences common stock at an exercise price of $0.88 per share. These options have an expiration date of May 6, 2028 and are held directly by the reporting person.

What stock options over TLSA shares are reported at the $0.71 exercise price?

The filing shows four option positions, each tied to 250,000 underlying common shares at an exercise price of $0.71 per share. These options share an expiration date of May 3, 2034 and are held as direct derivative positions by the insider.

Are the reported TLSA options immediately exercisable by Gabriele M. Cerrone?

A footnote states the options are exercisable upon the achievement of certain performance conditions. This means the rights to convert these options into common shares depend on meeting specified performance targets described in the related award terms.

Does the Form 3 for TLSA indicate any recent insider buying or selling activity?

No buy or sell transactions are indicated. The entries are classified as holdings, with unknown transaction codes and a neutral net buy-sell direction, meaning the document serves as an initial statement of existing ownership rather than reporting new trades.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 09:18 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CERRONE GABRIELE M

(Last) (First) (Middle)

C/O TIZIANA LIFESCIENCES LTD

14-15 CONDUIT STREET

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Tiziana Life Sciences Ltd [ TLSA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
COMMON STOCK	44,654,830	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	05/06/2028	Common stock	1,629,702	$0.88	D
Options	05/03/2025	05/03/2034	Common stock	250,000	$0.71	D
Options	05/03/2026	05/03/2034	Common stock	250,000	$0.71	D
Options	05/03/2027	05/03/2034	Common stock	250,000	$0.71	D
Options	05/03/2028	05/03/2034	Common stock	250,000	$0.71	D

Explanation of Responses:

1. Exercisable upon the achievement of certain performance conditions

	/s/ Gabriele Cerrone	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)